Drug Trial Radar · NCT04534075
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Sep 2, 2020
Primary completion
Sep 14, 2024
Study completion Sep 14, 2024
Sponsor
- Lead sponsor
- Sahlgrenska University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Swedish Research Council; VGregion; The Sjöberg Foundation
- First posted
- Sep 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators hypothesize that an increase in dietary fiber intake during radiation therapy may provide better long-term intestinal health for the cancer survivor. If the hypothesis is not correct, the increased intake may only mean an increase in acute side effects. All participants are advised to consume at least 16 g of dietary fiber/day via food. In addition, participants are invited to take capsules that together contain either 5.5 g of dietary fiber from psyllium husk or placebo.
Conditions
- Malignant Neoplasm
- Malignant Neoplasm of Rectum
- Malignant Neoplasm of Anus
- Malignant Neoplasm of Urinary Bladder
- Malignant Neoplasm of Cervix
- Malignant Neoplasm of Ovary
- Malignant Neoplasm of Prostate
- Malignant Neoplasm of Large Intestine
- Malignant Neoplasm of Colon
- Gynecologic Cancer
Interventions
Capsules containing either dietary fiber or placeboBiological
The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sign of inflammation i bloodTime frame: One month after the end of radiotherapy
- Intensity of the urgency syndromeTime frame: One year after the end of radiotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jubileumskliniken, Sahlgrenska University Hospital
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.